Rhone-Poulenc Rorer Azmacort HFA
Triamcinolone CFC-free inhaled steroid is deemed "approvable" by FDA April 30, for the second time. NDA 20-836 was originally submitted March 5, 1997 and was first "approvable" in March 1998. RPR submitted additional clinical data to the agency in response, which FDA accepted; the remaining issues are related to chemistry, manufacturing and controls. RPR says it will discuss with the agency what additional information is needed
You may also be interested in...
Kos Pharmaceuticals will relaunch Azmacort with a 490-representative sales force following its $200 mil. purchase of the inhaled corticosteroid from Aventis
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011